Genetic Profiling of Colorectal Carcinomas of Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Disease

Manon de Krijger, Beatriz Carvalho, Christian Rausch, Anne S. Bolijn, Pien M. Delis-van Diemen, Marianne Tijssen, Manon van Engeland, Nahid Mostafavi, Roel M. M. Bogie, Evelien Dekker, Ad A. M. Masclee, Joanne Verheij, Gerrit A. Meijer, Cyriel Y. Ponsioen

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Scopus)

Abstract

BACKGROUND: Patients with primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD) run a 10-fold increased risk of developing colorectal cancer (CRC) compared to patients with IBD only. The aim of this study was to perform an extensive screen of known carcinogenic genomic alterations in patients with PSC-IBD, and to investigate whether such changes occur already in nondysplastic mucosa. METHODS: Archival cancer tissue and nondysplastic mucosa from resection specimens of 19 patients with PSC-IBD-CRC were characterized, determining DNA copy-number variations, microsatellite instability (MSI), mutations on 48 cancer genes, and CpG island methylator phenotype (CIMP). Genetic profiles were compared with 2 published cohorts of IBD-associated CRC (IBD-CRC; n = 11) and sporadic CRC (s-CRC; n = 100). RESULTS: Patterns of chromosomal aberrations in PSC-IBD-CRC were similar to those observed in IBD-CRC and s-CRC, MSI occurred only once. Mutation frequencies were comparable between the groups, except for mutations in KRAS, which were less frequent in PSC-IBD-CRC (5%) versus IBD-CRC (38%) and s-CRC (31%; P = .034), and in APC, which were less frequent in PSC-IBD-CRC (5%) and IBD-CRC (0%) versus s-CRC (50%; P < .001). Cases of PSC-IBD-CRC were frequently CIMP positive (44%), at similar levels to cases of s-CRC (34%; P = .574) but less frequent than in cases with IBD-CRC (90%; P = .037). Similar copy number aberrations and mutations were present in matched cancers and adjacent mucosa in 5/15 and 7/11 patients, respectively. CONCLUSIONS: The excess risk of CRC in patients with PSC-IBD was not explained by copy number aberrations, mutations, MSI, nor CIMP status, in cancer tissue, nor in adjacent mucosa. These findings set the stage for further exome-wide and epigenetic studies.

Original languageEnglish
Pages (from-to)1309-1320
Number of pages12
JournalInflammatory Bowel Diseases
Volume28
Issue number9
DOIs
Publication statusPublished - 1 Sept 2022

Keywords

  • Cholangitis, Sclerosing/complications
  • Colorectal Neoplasms/complications
  • Genetic Profile
  • Humans
  • Inflammatory Bowel Diseases/complications
  • Microsatellite Instability
  • colorectal cancer
  • inflammatory bowel disease
  • primary sclerosing cholangitis

Cite this